WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
Jonathan Barratt(University of Leicester), Yusuke Suzuki(Juntendo University), Hitoshi Suzuki(Juntendo University Urayasu Hospital), Muh Geot Wong(FIND), Richard Lafayette(Stanford Medicine), Chula Herath(University of Sri Jayewardenepura), Sreelatha Melamadothil, Laura Kooeinga(Colorado Kidney Care), David Oldach(Visterra (United States)), Mohit Mathur(John Hunter Hospital), Asher D. Schachter(Visterra (United States))
Cited by 5
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification
|Kidney International|2009|1.2k
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group
|Kidney International|2017|1.2k
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility
|Kidney International|2009|1k
Human Decidual Natural Killer Cells Are a Unique NK Cell Subset with Immunomodulatory Potential
|The Journal of Experimental Medicine|2003|897